

Non-muscle Invasive Bladder Cancer Therapeutics Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/NE3405609704EN.html>

Date: June 2022

Pages: 112

Price: US\$ 3,250.00 (Single User License)

ID: NE3405609704EN

Abstracts

This report contains market size and forecasts of Non-muscle Invasive Bladder Cancer Therapeutics in Global, including the following market information:

Global Non-muscle Invasive Bladder Cancer Therapeutics Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Non-muscle Invasive Bladder Cancer Therapeutics market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Intravesical Chemotherapy Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Non-muscle Invasive Bladder Cancer Therapeutics include F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Eli Lilly and Company and Merck & Co., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-muscle Invasive Bladder Cancer Therapeutics companies, and industry experts on this industry,

involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Non-muscle Invasive Bladder Cancer Therapeutics Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Non-muscle Invasive Bladder Cancer Therapeutics Market Segment Percentages, by Type, 2021 (%)

Intravesical Chemotherapy

Intravesical Immunotherapy

Global Non-muscle Invasive Bladder Cancer Therapeutics Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Non-muscle Invasive Bladder Cancer Therapeutics Market Segment Percentages, by Application, 2021 (%)

Hospital

Ambulatory Surgery Center

Others

Global Non-muscle Invasive Bladder Cancer Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Non-muscle Invasive Bladder Cancer Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Non-muscle Invasive Bladder Cancer Therapeutics revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Non-muscle Invasive Bladder Cancer Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

F. Hoffmann-La Roche Ltd.

Bristol-Myers Squibb Company

AstraZeneca

Pfizer Inc.

GlaxoSmithKline plc.

Sanofi S.A.

Novartis AG

Eli Lilly and Company

Merck & Co.

Viventia Bio Inc.

Celgene Corporation

Spectrum Pharmaceuticals, Inc.

Herantis Pharma Plc.

Taris Biomedical LLC

Prometic Life Sciences Inc.

Telormediz S.A.

Heat Biologics

Altor BioScience

Ferring B.V.

Cold Genesys Inc.

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Non-muscle Invasive Bladder Cancer Therapeutics Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL NON-MUSCLE INVASIVE BLADDER CANCER THERAPEUTICS OVERALL MARKET SIZE

- 2.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size: 2021 VS 2028
- 2.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Non-muscle Invasive Bladder Cancer Therapeutics Players in Global Market
- 3.2 Top Global Non-muscle Invasive Bladder Cancer Therapeutics Companies Ranked by Revenue
- 3.3 Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Companies
- 3.4 Top 3 and Top 5 Non-muscle Invasive Bladder Cancer Therapeutics Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Non-muscle Invasive Bladder Cancer Therapeutics Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Non-muscle Invasive Bladder Cancer Therapeutics Players in Global Market

- 3.6.1 List of Global Tier 1 Non-muscle Invasive Bladder Cancer Therapeutics Companies
- 3.6.2 List of Global Tier 2 and Tier 3 Non-muscle Invasive Bladder Cancer Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

- 4.1.1 by Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Markets, 2021 & 2028
- 4.1.2 Intravesical Chemotherapy
- 4.1.3 Intravesical Immunotherapy

4.2 By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue & Forecasts

- 4.2.1 By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2022
- 4.2.2 By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2023-2028
- 4.2.3 By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

- 5.1.1 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2021 & 2028
- 5.1.2 Hospital
- 5.1.3 Ambulatory Surgery Center
- 5.1.4 Others

5.2 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue & Forecasts

- 5.2.1 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2022
- 5.2.2 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2023-2028
- 5.2.3 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2021 & 2028

6.2 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue & Forecasts

6.2.1 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2022

6.2.2 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2023-2028

6.2.3 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028

6.3.2 US Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.3.3 Canada Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.3.4 Mexico Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028

6.4.2 Germany Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.4.3 France Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.4.4 U.K. Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.4.5 Italy Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.4.6 Russia Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.4.7 Nordic Countries Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.4.8 Benelux Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028

6.5.2 China Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.5.3 Japan Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.5.4 South Korea Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.5.5 Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.5.6 India Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.6 South America
6.6.1 By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028

6.6.2 Brazil Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.6.3 Argentina Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028

6.7.2 Turkey Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.7.3 Israel Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.7.4 Saudi Arabia Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

6.7.5 UAE Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 F. Hoffmann-La Roche Ltd.

7.1.1 F. Hoffmann-La Roche Ltd. Corporate Summary

7.1.2 F. Hoffmann-La Roche Ltd. Business Overview

7.1.3 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings

7.1.4 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)

7.1.5 F. Hoffmann-La Roche Ltd. Key News

7.2 Bristol-Myers Squibb Company

7.2.1 Bristol-Myers Squibb Company Corporate Summary

7.2.2 Bristol-Myers Squibb Company Business Overview

7.2.3 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer

Therapeutics Major Product Offerings

7.2.4 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer

Therapeutics Revenue in Global Market (2017-2022)

7.2.5 Bristol-Myers Squibb Company Key News

7.3 AstraZeneca

7.3.1 AstraZeneca Corporate Summary

7.3.2 AstraZeneca Business Overview

7.3.3 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings

7.3.4 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)

7.3.5 AstraZeneca Key News

7.4 Pfizer Inc.

7.4.1 Pfizer Inc. Corporate Summary

7.4.2 Pfizer Inc. Business Overview

7.4.3 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings

7.4.4 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)

7.4.5 Pfizer Inc. Key News

7.5 GlaxoSmithKline plc.

7.5.1 GlaxoSmithKline plc. Corporate Summary

7.5.2 GlaxoSmithKline plc. Business Overview

7.5.3 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings

7.5.4 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)

7.5.5 GlaxoSmithKline plc. Key News

7.6 Sanofi S.A.

7.6.1 Sanofi S.A. Corporate Summary

7.6.2 Sanofi S.A. Business Overview

7.6.3 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings

7.6.4 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)

7.6.5 Sanofi S.A. Key News

7.7 Novartis AG

7.7.1 Novartis AG Corporate Summary

7.7.2 Novartis AG Business Overview

7.7.3 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings

7.7.4 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)

7.7.5 Novartis AG Key News

7.8 Eli Lilly and Company

7.8.1 Eli Lilly and Company Corporate Summary

7.8.2 Eli Lilly and Company Business Overview

7.8.3 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings

7.8.4 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)

7.8.5 Eli Lilly and Company Key News

7.9 Merck & Co.

7.9.1 Merck & Co. Corporate Summary

7.9.2 Merck & Co. Business Overview

7.9.3 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings

7.9.4 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)

7.9.5 Merck & Co. Key News

7.10 Viventia Bio Inc.

7.10.1 Viventia Bio Inc. Corporate Summary

7.10.2 Viventia Bio Inc. Business Overview

7.10.3 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings

7.10.4 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)

7.10.5 Viventia Bio Inc. Key News

7.11 Celgene Corporation

7.11.1 Celgene Corporation Corporate Summary

7.11.2 Celgene Corporation Business Overview

7.11.3 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings

7.11.4 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)

7.11.5 Celgene Corporation Key News

7.12 Spectrum Pharmaceuticals, Inc.

7.12.1 Spectrum Pharmaceuticals, Inc. Corporate Summary

- 7.12.2 Spectrum Pharmaceuticals, Inc. Business Overview
- 7.12.3 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
- 7.12.4 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
- 7.12.5 Spectrum Pharmaceuticals, Inc. Key News
- 7.13 Herantis Pharma Plc.
 - 7.13.1 Herantis Pharma Plc. Corporate Summary
 - 7.13.2 Herantis Pharma Plc. Business Overview
 - 7.13.3 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
 - 7.13.4 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
 - 7.13.5 Herantis Pharma Plc. Key News
- 7.14 Taris Biomedical LLC
 - 7.14.1 Taris Biomedical LLC Corporate Summary
 - 7.14.2 Taris Biomedical LLC Business Overview
 - 7.14.3 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
 - 7.14.4 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
 - 7.14.5 Taris Biomedical LLC Key News
- 7.15 Prometic Life Sciences Inc.
 - 7.15.1 Prometic Life Sciences Inc. Corporate Summary
 - 7.15.2 Prometic Life Sciences Inc. Business Overview
 - 7.15.3 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
 - 7.15.4 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
 - 7.15.5 Prometic Life Sciences Inc. Key News
- 7.16 Telormediz S.A.
 - 7.16.1 Telormediz S.A. Corporate Summary
 - 7.16.2 Telormediz S.A. Business Overview
 - 7.16.3 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
 - 7.16.4 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
 - 7.16.5 Telormediz S.A. Key News
- 7.17 Heat Biologics

- 7.17.1 Heat Biologics Corporate Summary
- 7.17.2 Heat Biologics Business Overview
- 7.17.3 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
- 7.17.4 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
- 7.17.5 Heat Biologics Key News
- 7.18 Altor BioScience
 - 7.18.1 Altor BioScience Corporate Summary
 - 7.18.2 Altor BioScience Business Overview
 - 7.18.3 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
 - 7.18.4 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
 - 7.18.5 Altor BioScience Key News
- 7.19 Ferring B.V.
 - 7.19.1 Ferring B.V. Corporate Summary
 - 7.19.2 Ferring B.V. Business Overview
 - 7.19.3 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
 - 7.19.4 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
 - 7.19.5 Ferring B.V. Key News
- 7.20 Cold Genesys Inc.
 - 7.20.1 Cold Genesys Inc. Corporate Summary
 - 7.20.2 Cold Genesys Inc. Business Overview
 - 7.20.3 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
 - 7.20.4 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
 - 7.20.5 Cold Genesys Inc. Key News

8 CONCLUSION

9 APPENDIX

- 9.1 Note
- 9.2 Examples of Clients
- 9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Non-muscle Invasive Bladder Cancer Therapeutics Market Opportunities & Trends in Global Market

Table 2. Non-muscle Invasive Bladder Cancer Therapeutics Market Drivers in Global Market

Table 3. Non-muscle Invasive Bladder Cancer Therapeutics Market Restraints in Global Market

Table 4. Key Players of Non-muscle Invasive Bladder Cancer Therapeutics in Global Market

Table 5. Top Non-muscle Invasive Bladder Cancer Therapeutics Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Share by Companies, 2017-2022

Table 8. Global Companies Non-muscle Invasive Bladder Cancer Therapeutics Product Type

Table 9. List of Global Tier 1 Non-muscle Invasive Bladder Cancer Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Non-muscle Invasive Bladder Cancer Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics

Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics

Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Non-muscle Invasive Bladder Cancer

Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Non-muscle Invasive Bladder Cancer

Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics

Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics

Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics

Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics

Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Non-muscle Invasive Bladder Cancer

Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Non-muscle Invasive Bladder Cancer

Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer

Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer

Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 30. F. Hoffmann-La Roche Ltd. Corporate Summary

Table 31. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer

Therapeutics Product Offerings

Table 32. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer

Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 33. Bristol-Myers Squibb Company Corporate Summary

Table 34. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer

Therapeutics Product Offerings

Table 35. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer

Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 36. AstraZeneca Corporate Summary

Table 37. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Product

Offerings

Table 38. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue

(US\$, Mn), (2017-2022)

Table 39. Pfizer Inc. Corporate Summary

Table 40. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings

Table 41. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 42. GlaxoSmithKline plc. Corporate Summary

Table 43. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings

Table 44. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 45. Sanofi S.A. Corporate Summary

Table 46. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings

Table 47. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 48. Novartis AG Corporate Summary

Table 49. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings

Table 50. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 51. Eli Lilly and Company Corporate Summary

Table 52. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings

Table 53. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 54. Merck & Co. Corporate Summary

Table 55. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings

Table 56. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 57. Viventia Bio Inc. Corporate Summary

Table 58. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings

Table 59. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 60. Celgene Corporation Corporate Summary

Table 61. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings

Table 62. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 63. Spectrum Pharmaceuticals, Inc. Corporate Summary

Table 64. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings

Table 65. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 66. Herantis Pharma Plc. Corporate Summary

Table 67. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings

Table 68. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 69. Taris Biomedical LLC Corporate Summary

Table 70. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings

Table 71. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 72. Prometic Life Sciences Inc. Corporate Summary

Table 73. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings

Table 74. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 75. Telormediz S.A. Corporate Summary

Table 76. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings

Table 77. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 78. Heat Biologics Corporate Summary

Table 79. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings

Table 80. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 81. Altor BioScience Corporate Summary

Table 82. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings

Table 83. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 84. Ferring B.V. Corporate Summary

Table 85. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings

Table 86. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue

(US\$, Mn), (2017-2022)

Table 87. Cold Genesys Inc. Corporate Summary

Table 88. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics
Product Offerings

Table 89. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics
Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Non-muscle Invasive Bladder Cancer Therapeutics Segment by Type in 2021
- Figure 2. Non-muscle Invasive Bladder Cancer Therapeutics Segment by Application in 2021
- Figure 3. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Non-muscle Invasive Bladder Cancer Therapeutics Revenue in 2021
- Figure 8. By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
- Figure 12. US Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
- Figure 16. Germany Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$,

Mn), 2017-2028

Figure 20. Russia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028

Figure 24. China Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 28. India Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028

Figure 30. Brazil Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028

Figure 33. Turkey Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 37. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 51. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 52. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 53. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 54. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 55. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 56. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Non-muscle Invasive Bladder Cancer Therapeutics Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/NE3405609704EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NE3405609704EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

